Amplia Therapeutics Partners With Eli Lilly for Lung Cancer Trial
Amplia Therapeutics has partnered with Eli Lilly and Company to evaluate its investigational FAK inhibitor narmafotinib alongside Lilly’s next-generation KRAS G12C inhibitor olomorasib in a phase 1b/2b clinical trial for advanced non-small cell lung cancer, targeting a major drug resistance mechanism in a global market. A new clinical trial agreement aims to tackle one of … Read more